Affimed (NASDAQ:AFMD) Lifted to “Hold” at Zacks Investment Research

Affimed (NASDAQ:AFMD) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company’s product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany. “

AFMD has been the topic of a number of other research reports. Stifel Nicolaus started coverage on Affimed in a research report on Wednesday, September 29th. They set a “buy” rating and a $12.00 price target on the stock. SVB Leerink dropped their price objective on Affimed from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $12.83.

Shares of AFMD traded up $0.10 during mid-day trading on Thursday, hitting $5.95. The company’s stock had a trading volume of 22,369 shares, compared to its average volume of 2,019,753. Affimed has a one year low of $3.09 and a one year high of $11.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.37 and a current ratio of 3.38. The firm has a market capitalization of $584.81 million, a PE ratio of -12.93 and a beta of 2.67. The stock’s 50-day moving average is $6.32 and its two-hundred day moving average is $7.70.

Affimed (NASDAQ:AFMD) last issued its earnings results on Tuesday, September 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.10). Affimed had a negative net margin of 91.76% and a negative return on equity of 34.91%. The firm had revenue of $11.70 million during the quarter, compared to analyst estimates of $13.57 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. Analysts expect that Affimed will post -0.34 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. boosted its holdings in shares of Affimed by 7.6% in the first quarter. Ameriprise Financial Inc. now owns 27,390 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 1,945 shares during the period. Price T Rowe Associates Inc. MD raised its position in Affimed by 5.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,695 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 2,010 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Affimed by 11.8% in the first quarter. Principal Financial Group Inc. now owns 24,066 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 2,541 shares during the period. Amalgamated Bank increased its holdings in shares of Affimed by 19.4% in the first quarter. Amalgamated Bank now owns 15,736 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 2,555 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Affimed by 1.2% in the second quarter. Russell Investments Group Ltd. now owns 214,253 shares of the biopharmaceutical company’s stock worth $1,819,000 after buying an additional 2,639 shares during the period. 72.98% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.

Read More: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.